Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound method could predict relapses in rare artery disease

NCT ID NCT07552636

Knowledge-focused Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 01, 2026 · Updated 2 times

Summary

This study tests whether ultrasound scans and patient questionnaires can better track disease activity in people with giant cell arteritis, a condition that inflames arteries and can cause blindness. Researchers will follow 175 patients in remission for one year, using ultrasound and blood samples to see if they can predict relapses. The goal is to improve monitoring and reduce reliance on steroids.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better tools for monitoring giant cell arteritis and predicting relapses, helping doctors tailor treatments and reduce long-term steroid use.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve health. The tools tested may not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 175 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with giant cell arteritis (ICD-10: M31.5, M31.6) in clinical remission but still undergoing glucocorticoid tapering or tapering of glucocorticoid-sparing treatment.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Clinical GCA diagnosis established/confirmed by a rheumatologist and positive GCA imaging or biopsy at diagnosis \< 3 years. 2. Clinical remission at the time of inclusion, defined as * Having adhered for ≥ 8 weeks prior to inclusion to either (a) the planned tapering of glucocorticoid therapy, or (b) the planned glucocorticoid-sparing DMARD treatment (with or without glucocorticoids). * Absence of, or no worsening of, symptoms attributed to GCA in ≥ 8 weeks. * Normal CRP level (\< 10 mg/L) within 7 days before inclusion. 3. Current prednisolone dosage of ≥ 5 mg if glucocorticoid monotherapy. 4. A continuous tapering of monotherapy or combination therapy is planned. 5. Age \> 50 years. 6. Study participants must be able to speak and understand spoken and written Danish. Exclusion Criteria: 1. Intra-articular, intravenous or intramuscular glucocorticoid ≤ 7 weeks prior to inclusion. 2. Study participants who are unable to complete online questionnaires cannot participate in the GCA-PRO component of the study. 3. Presence of cognitive impairment, including clinically significant dementia, that may interfere with the ability to provide informed consent or comply with study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Giant cell arteritis (GCA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Giant Cell Arteritis temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Giant cell arteritis (GCA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aalborg University Hospital, Department of Rheumatology

    NOT_YET_RECRUITING

    Aalborg, 9000, Denmark

  • Aarhus University Hospital, Department of Rheumatology

    RECRUITING

    Aarhus, 8200, Denmark

  • Hospitalsenhed Midt, Medicinsk Diagnostisk Center

    NOT_YET_RECRUITING

    Silkeborg, 8600, Denmark

  • Regional Hospital Horsens, Department of Medicine

    RECRUITING

    Horsens, 8700, Denmark

  • Rigshospitalet Glostrup, Center for Rheumatology and Spine Diseases Rigshospitalet

    RECRUITING

    Glostrup Municipality, 2600, Denmark

  • Svendborg Hospital, Department of Medicine

    NOT_YET_RECRUITING

    Svendborg, 5700, Denmark

  • Vejle Hospital, Department of Medicine

    RECRUITING

    Vejle, 7100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.